文献速递神经介入DSACT

使用血流重定向腔内装置治疗颅内及颅外动脉瘤:多中心经验与随访结果

Treatment of Intra- and Extracranial Aneurysms Using the Flow-Redirection Endoluminal Device: Multicenter Experience and Follow-Up Results.
PubMed 文献 · AJNR Am J Neuroradiol · 2016-11-03

该多中心回顾性分析纳入2013年3月至2016年2月4个神经血管中心使用FRED血流导向装置治疗的52例颅内动脉瘤,成功植入率96.2%,12个月随访完全闭塞率75.0%、近完全闭塞率22.2%,总体急性和晚期血栓栓塞及出血并发症率17.3%,永久性治疗相关病残率和死亡率分别为4.0%和2.0%。作者认为FRED是治疗颅内动脉瘤的有效工具,双层设计促进当代和稳定的长期闭塞率,充分的装置扩张应通过血管造影CT记录,进一步研究可能有助于确定更佳的抗血小板方案。

要点

  • FRED成功植入率为96.2%(50/52),12个月随访完全闭塞率为75.0%(27/36)。
  • 总体急性和晚期血栓栓塞及出血并发症率为17.3%(9/52),永久性治疗相关病残率为4.0%(2/50)、死亡率为2.0%(1/50)。
  • 充分的装置扩张应通过血管造影CT记录。

核心结论

  • FRED装置为颅内动脉瘤的治疗提供了有效工具,其双层设计促进了当代和稳定的长期闭塞率。
  • 充分的装置扩张应通过血管造影CT记录。
  • 进一步研究可能有助于确定更佳的抗血小板方案,以避免随访期间的血栓栓塞并发症。

研究设计与样本

  • 多中心回顾性分析,纳入2013年3月至2016年2月期间4个神经血管中心所有使用FRED治疗的颅内动脉瘤。
  • 共52例治疗,其中44例为未破裂动脉瘤,8例治疗因目标动脉瘤急性蛛网膜下腔出血。
  • 回顾性分析血管造影和临床结果,包括所有随访检查。

诊断标准与关键数值

  • 3个月随访时,完全闭塞为58.1%(25/43),近完全闭塞为25.6%(11/43)。
  • 12个月随访时,动脉瘤完全闭塞为75.0%(27/36),近完全闭塞为22.2%(8/36)。
  • FRED成功植入率为96.2%(50/52)。
  • 总体急性和晚期血栓栓塞及出血并发症率为17.3%(9/52)。
  • 永久性治疗相关病残率为4.0%(2/50),死亡率为2.0%(1/50)。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文为多中心回顾性分析。
  • 进一步研究可能有助于确定更佳的抗血小板方案,以避免随访期间的血栓栓塞并发症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Flow diversion emerged as a crucial treatment option for intracranial aneurysms. We report a multicenter retrospective analysis of the safety and efficacy in the treatment of intracranial aneurysms with the Flow-Redirection Endoluminal Device (FRED) flow diverter, a dual-layer flow-modulation device.

MATERIALS AND METHODS: All intracranial aneurysms treated with the FRED between March 2013 and February 2016 at 4 neurovascular centers were included. Angiographic and clinical results were retrospectively analyzed, including all follow-up examinations. Aneurysms were unruptured in 44 cases, whereas 8 treatments were due to an acute SAH from the target aneurysm.

RESULTS: Successful implantation of the FRED was possible in 96.2% (50/52) of cases. At 3-month follow-up, complete occlusion was determined in 58.1% (25/43) and near-complete in 25.6% (11/43). At 12-month follow-up, aneurysm occlusion was complete in 75.0% (27/36) and near-complete in 22.2% (8/36). The overall acute and late thromboembolic and hemorrhagic complication rate was 17.3% (9/52), with a permanent treatment-related morbidity and mortality of 4.0% (2/50) and 2.0% (1/50), respectively, to date.

CONCLUSIONS: The FRED device offers an effective tool in the treatment of intracranial aneurysms. The dual-layer design promotes contemporary and stable long-term occlusion rates. Sufficient device expansion should be documented by angiographic CT. Further studies might help to identify a more optimal antiplatelet regimen to avoid thromboembolic complications during the follow-up period.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Drescher F, Weber W, Berlis A, et al. Treatment of Intra- and Extracranial Aneurysms Using the Flow-Redirection Endoluminal Device: Multicenter Experience and Follow-Up Results. AJNR Am J Neuroradiol. 2016. PMID: 27811135. doi:10.3174/ajnr.A4964

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。